Robust evidence demonstrates the benefits of prompt AVR in patients with severe aortic stenosis (AS)1-5

In a real-world meta-analysis of over 1400 asymptomatic severe AS patients2:

Graph showing early AVR in patients prior to symptom onset significantly reduced rates of stroke

Early AVR in patients prior to symptom onset significantly reduced rates of stroke (pooled rate 4.5% vs 7.2%; HR: 0.62; 95% CI: 0.40-0.97; I2=0%; P=0.03)2

TAVR by Edwards is approved for severe AS patients regardless of symptoms

The EARLY TAVR trial proved that prompt intervention with TAVR by Edwards was superior to clinical surveillance in the primary composite endpoint of death, stroke, or unplanned cardiovascular hospitalization* in asymptomatic severe AS patients†1

Primary composite endpoint at 5 years†1:

Graph showing primary composite end point at 5 years from Early TAVR trial

*Including any aortic valve intervention or reintervention within 6 months.1

The EARLY TAVR trial is a prospective, multicenter RCT that compared early TAVR (SAPIEN 3/SAPIEN 3 Ultra) to guideline-recommended clinical surveillance among patients with asymptomatic severe AS. The primary endpoint was a composite of death, stroke, or unplanned cardiovascular hospitalization. Unplanned cardiovascular hospitalization includes any aortic valve intervention or reintervention within 6 months. Secondary endpoints included favorable health status outcome.1

There’s significant risk to watchful waiting for patients with severe AS1


Up to 38% graphic visualizing percent of patients with SAS who did not initially report symptoms revealed during functional testing

Even careful surveillance is twice as likely to result in unexpected or emergency cardiovascular hospitalization than receiving early treatment1

Nearly 50% graphic visualizing percent of patients diagnosed with moderate or severe AS who do not report symptoms

Prompt TAVR resulted in a 68% lower risk of hospitalization for heart failure through 5 years vs clinical surveillance (5.3% vs 12%)§1

Includes any unplanned cardiovascular hospitalization and any aortic valve intervention or reintervention within 6 months.1

§KM estimate at 5 years.1

TAVR for Asymptomatic Severe Aortic Stenosis: Results of the EARLY TAVR Trial

Watch video

For more details on the outcomes of the EARLY TAVR trial, use this link to access the New England Journal of Medicine publication. No registration is necessary.

New England Journal of Medicine thumbnail

New England Journal of Medicine
Transcatheter Aortic-Valve Replacement for Asymptomatic Severe Aortic Stenosis

Download

JACC Journals thumbnail

JACC Journals
Aortic Valve Replacement vs Clinical Surveillance in Asymptomatic Severe Aortic Stenosis: A Systematic Review and Meta-Analysis

Download
Edwards SAPIEN 3 Ultra valve

TAVR by Edwards is built for durability6

According to real-world studies:

  • Reintervention rates are exceedingly low with TAVR—over 98% of patients did not require valve reintervention after 10 years7
  • TAVR by Edwards demonstrates excellent structural integrity in accelerated wear testing; an equivalent of 25 years of wear with no differences compared to surgical valves8
  • Paravalvular leak (PVL) contributes to valve deterioration. The Edwards SAPIEN 3 Ultra valve demonstrated excellent PVL performance with 87% experiencing no/trace PVL at 30 days9,10
Thumbnail of TAVR Info Kit

READY TO HAVE THE TAVR DISCUSSION WITH YOUR PATIENT?

Download the TAVR Info Kit, which contains details about the procedure.

Download

Stay informed

Sign up for our newsletter to get the latest news about Edwards and heart valve health.

Sign up for the newsletter
Icon of a brochure

Identify who is right for TAVR?

See the broadened eligibility of TAVR.

View patient types
Icon of a magnifying glass
References: 1.Généreux P, Schwartz A, Oldemeyer JB, et al. Transcatheter aortic-valve replacement for asymptomatic severe aortic stenosis. N Engl J Med. 2025;392(3):217-227. 2.Généreux P, Banovic M, Kang DH, et al. Aortic valve replacement vs clinical surveillance in asymptomatic severe aortic stenosis: a systematic review and meta-analysis. J Am Coll Cardiol. 2025;85(9):912-922. 3.Otto CM. Timing of aortic valve surgery. Heart. 2000;84(2):211-218. 4.Treibel TA, Kozor R, Schofield R, et al. Reverse myocardial remodeling following valve replacement in patients with aortic stenosis. J Am Coll Cardiol. 2018;71(8):860-871. 5.Malaisrie SC, McDonald E, Kruse J, et al. Mortality while waiting for aortic valve replacement. Ann Thorac Surg. 2014;98(5):1564-1571. 6.Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic-valve replacement in low-risk patients at five years. N Engl J Med. 2023;389(21):1949-1960. 7.Baron SJ, Ryan MP, Chikermane SG, Thompson C, Clancy S, Gunnarsson CL. Long-term risk of reintervention after transcatheter aortic valve replacement. Am Heart J. 2024;267:44-51. 8.Sathananthan J, Hensey M, Landes U, et al. Long-term durability of transcatheter heart valves: insights from bench testing to 25 years. JACC Cardiovasc Interv. 2020;13(2):235-249. 9.Généreux P, Piazza N, Alu MC, et al. Valve Academic Research Consortium 3: updated endpoint definitions for aortic valve clinical research. Eur Heart J. 2021;42(19):1825-1857. 10.Nazif TM, Cahill TJ, Daniels D, et al. Real-world experience with the SAPIEN 3 Ultra transcatheter heart valve: a propensity-matched analysis from the United States. Circ Cardiovasc Interv. 2021;14(9):e010543.

Patients and/or clinicians quoted on this website have received compensation from Edwards Lifesciences.